Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of apatinib for gastric cancer
ChiCTR1800017662Phase 4Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Aug 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Safety. Started Aug 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1800017662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017662.